LMNA and Hutchinson-Gilford progeria syndrome: In this regard, an immunoassay has recently been optimized to detect progerin in the plasma of patients with HGPS as a valuable method to monitor clinical outcomes derived from progerin‐targeted therapies (Gordon et al., 2023).